New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular la...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Monika Małgorzata Adamska [verfasserIn] Ewelina Kowal-Wiśniewska [verfasserIn] Katarzyna Kiwerska [verfasserIn] Adam Ustaszewski [verfasserIn] Joanna Czerwińska-Rybak [verfasserIn] Zuzanna Kanduła [verfasserIn] Marzena Wojtaszewska [verfasserIn] Marta Barańska [verfasserIn] Łukasz Pruchniewski [verfasserIn] Krzysztof Lewandowski [verfasserIn] Małgorzata Jarmuż-Szymczak [verfasserIn] Lidia Gil [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
secondary acute myeloid leukemia |
|---|
| Übergeordnetes Werk: |
In: Central European Journal of Immunology - Termedia Publishing House, 2017, 46(2021), 4, Seite 524-530 |
|---|---|
| Übergeordnetes Werk: |
volume:46 ; year:2021 ; number:4 ; pages:524-530 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.5114/ceji.2021.111166 |
|---|
| Katalog-ID: |
DOAJ030758459 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030758459 | ||
| 003 | DE-627 | ||
| 005 | 20230307152800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5114/ceji.2021.111166 |2 doi | |
| 035 | |a (DE-627)DOAJ030758459 | ||
| 035 | |a (DE-599)DOAJ20b5762fa4954829927cac76a5439756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Monika Małgorzata Adamska |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. | ||
| 650 | 4 | |a ngs | |
| 650 | 4 | |a myelodysplastic syndrome | |
| 650 | 4 | |a secondary acute myeloid leukemia | |
| 650 | 4 | |a allogenic hematopoietic cell transplantation | |
| 650 | 4 | |a dna sequence variants/mutations. | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Ewelina Kowal-Wiśniewska |e verfasserin |4 aut | |
| 700 | 0 | |a Katarzyna Kiwerska |e verfasserin |4 aut | |
| 700 | 0 | |a Adam Ustaszewski |e verfasserin |4 aut | |
| 700 | 0 | |a Joanna Czerwińska-Rybak |e verfasserin |4 aut | |
| 700 | 0 | |a Zuzanna Kanduła |e verfasserin |4 aut | |
| 700 | 0 | |a Marzena Wojtaszewska |e verfasserin |4 aut | |
| 700 | 0 | |a Marta Barańska |e verfasserin |4 aut | |
| 700 | 0 | |a Łukasz Pruchniewski |e verfasserin |4 aut | |
| 700 | 0 | |a Krzysztof Lewandowski |e verfasserin |4 aut | |
| 700 | 0 | |a Małgorzata Jarmuż-Szymczak |e verfasserin |4 aut | |
| 700 | 0 | |a Lidia Gil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Central European Journal of Immunology |d Termedia Publishing House, 2017 |g 46(2021), 4, Seite 524-530 |w (DE-627)511229127 |w (DE-600)2233185-2 |x 16444124 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:4 |g pages:524-530 |
| 856 | 4 | 0 | |u https://doi.org/10.5114/ceji.2021.111166 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/20b5762fa4954829927cac76a5439756 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1426-3912 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1644-4124 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 4 |h 524-530 | ||
| author_variant |
m m a mma e k w ekw k k kk a u au j c r jcr z k zk m w mw m b mb ł p łp k l kl m j s mjs l g lg |
|---|---|
| matchkey_str |
article:16444124:2021----::egntcainsfe2nax1dniidyeteeaineunignprsqecniaainwtms |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.5114/ceji.2021.111166 doi (DE-627)DOAJ030758459 (DE-599)DOAJ20b5762fa4954829927cac76a5439756 DE-627 ger DE-627 rakwb eng Monika Małgorzata Adamska verfasserin aut New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations. Medicine R Ewelina Kowal-Wiśniewska verfasserin aut Katarzyna Kiwerska verfasserin aut Adam Ustaszewski verfasserin aut Joanna Czerwińska-Rybak verfasserin aut Zuzanna Kanduła verfasserin aut Marzena Wojtaszewska verfasserin aut Marta Barańska verfasserin aut Łukasz Pruchniewski verfasserin aut Krzysztof Lewandowski verfasserin aut Małgorzata Jarmuż-Szymczak verfasserin aut Lidia Gil verfasserin aut In Central European Journal of Immunology Termedia Publishing House, 2017 46(2021), 4, Seite 524-530 (DE-627)511229127 (DE-600)2233185-2 16444124 nnns volume:46 year:2021 number:4 pages:524-530 https://doi.org/10.5114/ceji.2021.111166 kostenfrei https://doaj.org/article/20b5762fa4954829927cac76a5439756 kostenfrei https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html kostenfrei https://doaj.org/toc/1426-3912 Journal toc kostenfrei https://doaj.org/toc/1644-4124 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 46 2021 4 524-530 |
| spelling |
10.5114/ceji.2021.111166 doi (DE-627)DOAJ030758459 (DE-599)DOAJ20b5762fa4954829927cac76a5439756 DE-627 ger DE-627 rakwb eng Monika Małgorzata Adamska verfasserin aut New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations. Medicine R Ewelina Kowal-Wiśniewska verfasserin aut Katarzyna Kiwerska verfasserin aut Adam Ustaszewski verfasserin aut Joanna Czerwińska-Rybak verfasserin aut Zuzanna Kanduła verfasserin aut Marzena Wojtaszewska verfasserin aut Marta Barańska verfasserin aut Łukasz Pruchniewski verfasserin aut Krzysztof Lewandowski verfasserin aut Małgorzata Jarmuż-Szymczak verfasserin aut Lidia Gil verfasserin aut In Central European Journal of Immunology Termedia Publishing House, 2017 46(2021), 4, Seite 524-530 (DE-627)511229127 (DE-600)2233185-2 16444124 nnns volume:46 year:2021 number:4 pages:524-530 https://doi.org/10.5114/ceji.2021.111166 kostenfrei https://doaj.org/article/20b5762fa4954829927cac76a5439756 kostenfrei https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html kostenfrei https://doaj.org/toc/1426-3912 Journal toc kostenfrei https://doaj.org/toc/1644-4124 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 46 2021 4 524-530 |
| allfields_unstemmed |
10.5114/ceji.2021.111166 doi (DE-627)DOAJ030758459 (DE-599)DOAJ20b5762fa4954829927cac76a5439756 DE-627 ger DE-627 rakwb eng Monika Małgorzata Adamska verfasserin aut New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations. Medicine R Ewelina Kowal-Wiśniewska verfasserin aut Katarzyna Kiwerska verfasserin aut Adam Ustaszewski verfasserin aut Joanna Czerwińska-Rybak verfasserin aut Zuzanna Kanduła verfasserin aut Marzena Wojtaszewska verfasserin aut Marta Barańska verfasserin aut Łukasz Pruchniewski verfasserin aut Krzysztof Lewandowski verfasserin aut Małgorzata Jarmuż-Szymczak verfasserin aut Lidia Gil verfasserin aut In Central European Journal of Immunology Termedia Publishing House, 2017 46(2021), 4, Seite 524-530 (DE-627)511229127 (DE-600)2233185-2 16444124 nnns volume:46 year:2021 number:4 pages:524-530 https://doi.org/10.5114/ceji.2021.111166 kostenfrei https://doaj.org/article/20b5762fa4954829927cac76a5439756 kostenfrei https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html kostenfrei https://doaj.org/toc/1426-3912 Journal toc kostenfrei https://doaj.org/toc/1644-4124 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 46 2021 4 524-530 |
| allfieldsGer |
10.5114/ceji.2021.111166 doi (DE-627)DOAJ030758459 (DE-599)DOAJ20b5762fa4954829927cac76a5439756 DE-627 ger DE-627 rakwb eng Monika Małgorzata Adamska verfasserin aut New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations. Medicine R Ewelina Kowal-Wiśniewska verfasserin aut Katarzyna Kiwerska verfasserin aut Adam Ustaszewski verfasserin aut Joanna Czerwińska-Rybak verfasserin aut Zuzanna Kanduła verfasserin aut Marzena Wojtaszewska verfasserin aut Marta Barańska verfasserin aut Łukasz Pruchniewski verfasserin aut Krzysztof Lewandowski verfasserin aut Małgorzata Jarmuż-Szymczak verfasserin aut Lidia Gil verfasserin aut In Central European Journal of Immunology Termedia Publishing House, 2017 46(2021), 4, Seite 524-530 (DE-627)511229127 (DE-600)2233185-2 16444124 nnns volume:46 year:2021 number:4 pages:524-530 https://doi.org/10.5114/ceji.2021.111166 kostenfrei https://doaj.org/article/20b5762fa4954829927cac76a5439756 kostenfrei https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html kostenfrei https://doaj.org/toc/1426-3912 Journal toc kostenfrei https://doaj.org/toc/1644-4124 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 46 2021 4 524-530 |
| allfieldsSound |
10.5114/ceji.2021.111166 doi (DE-627)DOAJ030758459 (DE-599)DOAJ20b5762fa4954829927cac76a5439756 DE-627 ger DE-627 rakwb eng Monika Małgorzata Adamska verfasserin aut New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations. Medicine R Ewelina Kowal-Wiśniewska verfasserin aut Katarzyna Kiwerska verfasserin aut Adam Ustaszewski verfasserin aut Joanna Czerwińska-Rybak verfasserin aut Zuzanna Kanduła verfasserin aut Marzena Wojtaszewska verfasserin aut Marta Barańska verfasserin aut Łukasz Pruchniewski verfasserin aut Krzysztof Lewandowski verfasserin aut Małgorzata Jarmuż-Szymczak verfasserin aut Lidia Gil verfasserin aut In Central European Journal of Immunology Termedia Publishing House, 2017 46(2021), 4, Seite 524-530 (DE-627)511229127 (DE-600)2233185-2 16444124 nnns volume:46 year:2021 number:4 pages:524-530 https://doi.org/10.5114/ceji.2021.111166 kostenfrei https://doaj.org/article/20b5762fa4954829927cac76a5439756 kostenfrei https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html kostenfrei https://doaj.org/toc/1426-3912 Journal toc kostenfrei https://doaj.org/toc/1644-4124 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 46 2021 4 524-530 |
| language |
English |
| source |
In Central European Journal of Immunology 46(2021), 4, Seite 524-530 volume:46 year:2021 number:4 pages:524-530 |
| sourceStr |
In Central European Journal of Immunology 46(2021), 4, Seite 524-530 volume:46 year:2021 number:4 pages:524-530 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations. Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Central European Journal of Immunology |
| authorswithroles_txt_mv |
Monika Małgorzata Adamska @@aut@@ Ewelina Kowal-Wiśniewska @@aut@@ Katarzyna Kiwerska @@aut@@ Adam Ustaszewski @@aut@@ Joanna Czerwińska-Rybak @@aut@@ Zuzanna Kanduła @@aut@@ Marzena Wojtaszewska @@aut@@ Marta Barańska @@aut@@ Łukasz Pruchniewski @@aut@@ Krzysztof Lewandowski @@aut@@ Małgorzata Jarmuż-Szymczak @@aut@@ Lidia Gil @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
511229127 |
| id |
DOAJ030758459 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030758459</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307152800.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5114/ceji.2021.111166</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030758459</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ20b5762fa4954829927cac76a5439756</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Monika Małgorzata Adamska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ngs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">myelodysplastic syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">secondary acute myeloid leukemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allogenic hematopoietic cell transplantation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna sequence variants/mutations.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ewelina Kowal-Wiśniewska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katarzyna Kiwerska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adam Ustaszewski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Czerwińska-Rybak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zuzanna Kanduła</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marzena Wojtaszewska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Barańska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Łukasz Pruchniewski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Krzysztof Lewandowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Małgorzata Jarmuż-Szymczak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lidia Gil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Central European Journal of Immunology</subfield><subfield code="d">Termedia Publishing House, 2017</subfield><subfield code="g">46(2021), 4, Seite 524-530</subfield><subfield code="w">(DE-627)511229127</subfield><subfield code="w">(DE-600)2233185-2</subfield><subfield code="x">16444124</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:46</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:524-530</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5114/ceji.2021.111166</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/20b5762fa4954829927cac76a5439756</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1426-3912</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1644-4124</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">46</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">524-530</subfield></datafield></record></collection>
|
| author |
Monika Małgorzata Adamska |
| spellingShingle |
Monika Małgorzata Adamska misc ngs misc myelodysplastic syndrome misc secondary acute myeloid leukemia misc allogenic hematopoietic cell transplantation misc dna sequence variants/mutations. misc Medicine misc R New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia |
| authorStr |
Monika Małgorzata Adamska |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)511229127 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
16444124 |
| topic_title |
New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia ngs myelodysplastic syndrome secondary acute myeloid leukemia allogenic hematopoietic cell transplantation dna sequence variants/mutations |
| topic |
misc ngs misc myelodysplastic syndrome misc secondary acute myeloid leukemia misc allogenic hematopoietic cell transplantation misc dna sequence variants/mutations. misc Medicine misc R |
| topic_unstemmed |
misc ngs misc myelodysplastic syndrome misc secondary acute myeloid leukemia misc allogenic hematopoietic cell transplantation misc dna sequence variants/mutations. misc Medicine misc R |
| topic_browse |
misc ngs misc myelodysplastic syndrome misc secondary acute myeloid leukemia misc allogenic hematopoietic cell transplantation misc dna sequence variants/mutations. misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Central European Journal of Immunology |
| hierarchy_parent_id |
511229127 |
| hierarchy_top_title |
Central European Journal of Immunology |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)511229127 (DE-600)2233185-2 |
| title |
New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia |
| ctrlnum |
(DE-627)DOAJ030758459 (DE-599)DOAJ20b5762fa4954829927cac76a5439756 |
| title_full |
New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia |
| author_sort |
Monika Małgorzata Adamska |
| journal |
Central European Journal of Immunology |
| journalStr |
Central European Journal of Immunology |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
524 |
| author_browse |
Monika Małgorzata Adamska Ewelina Kowal-Wiśniewska Katarzyna Kiwerska Adam Ustaszewski Joanna Czerwińska-Rybak Zuzanna Kanduła Marzena Wojtaszewska Marta Barańska Łukasz Pruchniewski Krzysztof Lewandowski Małgorzata Jarmuż-Szymczak Lidia Gil |
| container_volume |
46 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Monika Małgorzata Adamska |
| doi_str_mv |
10.5114/ceji.2021.111166 |
| author2-role |
verfasserin |
| title_sort |
new genetic variants of tet2 and asxl1 identified by next generation sequencing and pyrosequencing in a patient with mds-rs-mld and secondary acute myeloid leukemia |
| title_auth |
New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia |
| abstract |
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. |
| abstractGer |
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. |
| abstract_unstemmed |
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
4 |
| title_short |
New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia |
| url |
https://doi.org/10.5114/ceji.2021.111166 https://doaj.org/article/20b5762fa4954829927cac76a5439756 https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html https://doaj.org/toc/1426-3912 https://doaj.org/toc/1644-4124 |
| remote_bool |
true |
| author2 |
Ewelina Kowal-Wiśniewska Katarzyna Kiwerska Adam Ustaszewski Joanna Czerwińska-Rybak Zuzanna Kanduła Marzena Wojtaszewska Marta Barańska Łukasz Pruchniewski Krzysztof Lewandowski Małgorzata Jarmuż-Szymczak Lidia Gil |
| author2Str |
Ewelina Kowal-Wiśniewska Katarzyna Kiwerska Adam Ustaszewski Joanna Czerwińska-Rybak Zuzanna Kanduła Marzena Wojtaszewska Marta Barańska Łukasz Pruchniewski Krzysztof Lewandowski Małgorzata Jarmuż-Szymczak Lidia Gil |
| ppnlink |
511229127 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.5114/ceji.2021.111166 |
| up_date |
2024-07-03T16:49:03.479Z |
| _version_ |
1803577294566981632 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ030758459</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307152800.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5114/ceji.2021.111166</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ030758459</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ20b5762fa4954829927cac76a5439756</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Monika Małgorzata Adamska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by the presence of cytopenias, ineffective hematopoiesis and frequent transformation into secondary acute myeloid leukemia (secAML). Recent genomic studies provide unprecedented insight into the molecular landscape of clonal proliferation in MDS. Genetic diversity of both MDS and secAML subclones cannot be defined by a single somatic mutation. Mutations of the founding clone may survive over implemented chemotherapy and allogenic hematopoietic cell transplantation (alloHCT), but new subclonal mutations may also appear. Next generation sequencing (NGS) makes it possible to define the mutational profile of disease subclones during the treatment course and has a potential in pre- and post-alloHCT monitoring. Understanding the molecular pathophysiology of MDS may soon allow for monitoring the course of disease and personalized treatment depending on the mutational landscape. In the present paper we report, for the first time in MDS, ASXL1 c.1945G<T, TET2 c.4044+2dupT and c.4076G<T sequence variants. Moreover, we detected RUNX1 c.509-2A<C and SF3B1 c.1874G<T sequence variants. Furthermore, we verify the clinical utility of NGS and pyrosequencing in MDS and secAML.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ngs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">myelodysplastic syndrome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">secondary acute myeloid leukemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allogenic hematopoietic cell transplantation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna sequence variants/mutations.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ewelina Kowal-Wiśniewska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katarzyna Kiwerska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adam Ustaszewski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Czerwińska-Rybak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zuzanna Kanduła</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marzena Wojtaszewska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Barańska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Łukasz Pruchniewski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Krzysztof Lewandowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Małgorzata Jarmuż-Szymczak</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lidia Gil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Central European Journal of Immunology</subfield><subfield code="d">Termedia Publishing House, 2017</subfield><subfield code="g">46(2021), 4, Seite 524-530</subfield><subfield code="w">(DE-627)511229127</subfield><subfield code="w">(DE-600)2233185-2</subfield><subfield code="x">16444124</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:46</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:524-530</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5114/ceji.2021.111166</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/20b5762fa4954829927cac76a5439756</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.termedia.pl/New-genetic-variants-of-TET2-and-ASXL1-identified-by-next-generation-sequencing-and-pyrosequencing-in-a-patient-with-MDS-RS-MLD-and-secondary-acute-myeloid-leukemia,10,45715,1,1.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1426-3912</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1644-4124</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">46</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">524-530</subfield></datafield></record></collection>
|
| score |
7.399419 |